Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Status:
Withdrawn
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
Despite aggressive surgery and chemotherapy, the risk of lung cancer recurrence remains high
in most patients. This study aims to determine if a novel immune therapy consisting of two
drugs is feasible and potentially increases the chance of cure in lung cancer patients after
surgery and standard chemotherapy. The immune-based therapy being given in this study
consists of two medications named durvalumab and tremelimumab.